LianBio
This is the stock with the biggest upside potential and is another micro-cap biotech idea for aggressive traders. LianBio (NASDAQ: LIAN), a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, ophthalmology and inflammatory diseases in China and other Asian countries.
The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn’s disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.
LianBio has a partnership with Tarsus Pharmaceuticals to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis. It has a partnership with Nanobiotix to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy.
The $15 target price at Raymond James is well above the $9.73 consensus and a share price of $1.40 seen on Friday. The Raymond James target represents about a 971% gain.
Viking Therapeutics
Shares of this small-cap clinical-stage biopharmaceutical company could have monster upside potential. Viking Therapeutics Inc. (NASDAQ: VKTX) is focused on the development of novel therapies for metabolic and endocrine disorders.
Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as non-alcoholic fatty liver disease.
The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase 2 clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. Its VK0612 is an orally available Phase 2beady drug candidate for type 2 diabetes, and VK0214 is an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta for X-linked adrenoleukodystrophy.
Over the past year, insiders have been loading up on the shares, with a director at the firm buying 50,000 shares.
Raymond James has set its price objective at $11. The consensus target is higher at $17.44, and the stock traded at $3.70 on Friday. Hitting the target would be about a 200% gain.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with absolutely no track record or liquidity, and Raymond James has research coverage.
Originally published at 24/7 Wall St.
Sponsored: Tips for Investing
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
